268 related articles for article (PubMed ID: 27406986)
1. Concepts to Target MYC in Pancreatic Cancer.
Wirth M; Mahboobi S; Krämer OH; Schneider G
Mol Cancer Ther; 2016 Aug; 15(8):1792-8. PubMed ID: 27406986
[TBL] [Abstract][Full Text] [Related]
2. Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma.
Sahu N; Chan E; Chu F; Pham T; Koeppen H; Forrest W; Merchant M; Settleman J
Mol Cancer Ther; 2017 Sep; 16(9):1729-1738. PubMed ID: 28619758
[TBL] [Abstract][Full Text] [Related]
3. FASTKD2 promotes cancer cell progression through upregulating Myc expression in pancreatic ductal adenocarcinoma.
Fang R; Zhang B; Lu X; Jin X; Liu T
J Cell Biochem; 2020 Mar; 121(3):2458-2466. PubMed ID: 31692063
[TBL] [Abstract][Full Text] [Related]
4. β2-adrenergic receptor signaling promotes pancreatic ductal adenocarcinoma (PDAC) progression through facilitating PCBP2-dependent c-myc expression.
Wan C; Gong C; Zhang H; Hua L; Li X; Chen X; Chen Y; Ding X; He S; Cao W; Wang Y; Fan S; Xiao Y; Zhou G; Shen A
Cancer Lett; 2016 Apr; 373(1):67-76. PubMed ID: 26803058
[TBL] [Abstract][Full Text] [Related]
5. Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer.
Beglyarova N; Banina E; Zhou Y; Mukhamadeeva R; Andrianov G; Bobrov E; Lysenko E; Skobeleva N; Gabitova L; Restifo D; Pressman M; Serebriiskii IG; Hoffman JP; Paz K; Behrens D; Khazak V; Jablonski SA; Golemis EA; Weiner LM; Astsaturov I
Clin Cancer Res; 2016 Dec; 22(24):6153-6163. PubMed ID: 27384421
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivity.
Zheng Q; Tang J; Aicher A; Bou Kheir T; Sabanovic B; Ananthanarayanan P; Reina C; Chen M; Gu JM; He B; Alcala S; Behrens D; Lawlo RT; Scarpa A; Hidalgo M; Sainz B; Sancho P; Heeschen C
J Exp Clin Cancer Res; 2023 Nov; 42(1):323. PubMed ID: 38012687
[TBL] [Abstract][Full Text] [Related]
7. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells.
Liang C; Shi S; Liu M; Qin Y; Meng Q; Hua J; Ji S; Zhang Y; Yang J; Xu J; Ni Q; Li M; Yu X
Cancer Res; 2019 Jan; 79(1):133-145. PubMed ID: 30355620
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer.
Stellas D; Szabolcs M; Koul S; Li Z; Polyzos A; Anagnostopoulos C; Cournia Z; Tamvakopoulos C; Klinakis A; Efstratiadis A
J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25306215
[TBL] [Abstract][Full Text] [Related]
9. Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer.
Blake DR; Vaseva AV; Hodge RG; Kline MP; Gilbert TSK; Tyagi V; Huang D; Whiten GC; Larson JE; Wang X; Pearce KH; Herring LE; Graves LM; Frye SV; Emanuele MJ; Cox AD; Der CJ
Sci Signal; 2019 Jul; 12(590):. PubMed ID: 31311847
[TBL] [Abstract][Full Text] [Related]
10. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
11. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
12. A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer.
Henry KE; Dacek MM; Dilling TR; Caen JD; Fox IL; Evans MJ; Lewis JS
Clin Cancer Res; 2019 Jan; 25(1):166-176. PubMed ID: 30228208
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
14. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
[TBL] [Abstract][Full Text] [Related]
15. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype.
Biederstädt A; Hassan Z; Schneeweis C; Schick M; Schneider L; Muckenhuber A; Hong Y; Siegers G; Nilsson L; Wirth M; Dantes Z; Steiger K; Schunck K; Langston S; Lenhof HP; Coluccio A; Orben F; Slawska J; Scherger A; Saur D; Müller S; Rad R; Weichert W; Nilsson J; Reichert M; Schneider G; Keller U
Gut; 2020 Aug; 69(8):1472-1482. PubMed ID: 32001555
[TBL] [Abstract][Full Text] [Related]
16. DFMO Improves Survival and Increases Immune Cell Infiltration in Association with MYC Downregulation in the Pancreatic Tumor Microenvironment.
Nakkina SP; Gitto SB; Beardsley JM; Pandey V; Rohr MW; Parikh JG; Phanstiel O; Altomare DA
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947972
[TBL] [Abstract][Full Text] [Related]
17. miR-29a Is Repressed by MYC in Pancreatic Cancer and Its Restoration Drives Tumor-Suppressive Effects via Downregulation of LOXL2.
Dey S; Kwon JJ; Liu S; Hodge GA; Taleb S; Zimmers TA; Wan J; Kota J
Mol Cancer Res; 2020 Feb; 18(2):311-323. PubMed ID: 31662451
[TBL] [Abstract][Full Text] [Related]
18. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity.
Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY
Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671
[TBL] [Abstract][Full Text] [Related]
19. Critical role of oncogenic KRAS in pancreatic cancer (Review).
Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
[TBL] [Abstract][Full Text] [Related]
20. The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma.
García-Reyes B; Kretz AL; Ruff JP; von Karstedt S; Hillenbrand A; Knippschild U; Henne-Bruns D; Lemke J
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30340359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
